Abstract
This research service covers the U.S. smoking cessation drug market from
2003-2013. Included are a therapeutic overview, patient forecasts, total
market revenue forecasts, product revenue forecasts, and market share
analysis. The market is segmented by product: Zyban, Chantix, and emerging
products. Major market challenges, drivers, restraints, and strategic
recommendations to overcome market challenges are also discussed.
View Cart
